Oxagen Limited Raises $60 Million In Series B 
10/19/2005 5:09:50 PM

May 24, 2005 -- Continuing the trend of large early rounds, British company Oxagen, reported yesterday that it raised $59.8 million (£31.6 million) in a Series B round led by MPM Capital. Oxagen is focused on G-coupled protein receptors or GPCRs, as they are known. The target class is the most successful one so far, with over half the drugs currently on the market targeting these receptors. But it is also in the realm of big pharma. Developing drugs for indications like asthma and inflammation, which affect the overall population, is a major undertaking. We look at the history behind this company and its prospects...